Abstract: A novel method of protecting blood coagulation factor IX from proteases during purification or storage is disclosed. High concentrations of one or more water soluble organic or inorganic salts are used to stabilize factor IX, contained within blood plasma-derived solutions, or contained within solutions derived from other sources, against conversion to clinically unacceptable peptide structures such as factor IXa, and/or degraded factor IX peptides. The technique is useful in stabilizing intermediate purity factor IX preparations during purification, and in maintaining the integrity of purified factor IX during long term storage. Stable high specific activity factor IX preparations are also disclosed.

Abstract: A novel method of protecting blood coagulation factor IX from proteases during purification or storage is disclosed. High concentrations of one or more water soluble organic or inorganic salts are used to stabilize factor IX, contained within blood plasma-derived solutions, or contained within solutions derived from other sources, against conversion to clinically unacceptable peptide structures such as factor IX.sub.a, and/or degraded factor IX peptides. The technique is useful in stabilizing intermediate purity factor IX preparations during purification, and in maintaining the integrity of purified factor IX during long term storage. Stable high specific activity factor IX preparations are also disclosed.

Abstract: A novel method of protecting blood coagulation factor IX from proteases during purification or storage is disclosed. High concentrations of one or more water soluble organic or inorganic salts are used to stabilize factor IX, contained within blood plasma-derived solutions, or contained within solutions derived from other sources, against conversion to clinically unacceptable peptide structures such as factor IX.sub.a, and/or degraded factor IX peptides.The technique is useful in stabilizing intermediate purity factor IX preparations during purification, and in maintaining the integrity of purified factor IX during long term storage. Stable high specific activity factor IX preparations are also disclosed.

Abstract: A CMOS integrated circuit assembly for providing reduced power supply and ground inductances has a first conducting layer which is formed over an insulating layer formed on top of the integrated-circuit chip. The first conducting layer is connected to wire bond pads which are wirebonded to a package. This first conducting layer forms a single, low-inductance conductor for a VDD supply voltage and extends over a substantial area so that it has an inductance significantly less than the inductance of a conventional conductor. A second conducting layer is forms a low-inductance VSS conductor. Power can be selectively distributed through conductive layers of this to provide power supply isolation between selected circuits of the integrated circuit.

Abstract: A multi-functional exercising machine includes a main structure, a jogging device, a rowing device, a stationary bicycle, a pulling spring, a shelf, a stand, a chair, and a pull-up bar. The stand is attached to the main structure while standing on the jogging device. The chair or the pull-up bar is attachable to the stand.

Abstract: Silylated polyester resins comprising the acid salt of a Michael addition adduct of an aminoorganosilane and a conjugated unsaturated polyester resin containing a polyethylene oxide chain segment useful for sizing glass fiber reinforcement of polyester molding composites.

Abstract: A method comprising forming a water-in-oil emulsion of an aqueous phase comprising discrete water-insoluble particles an an aqueous solution of a water-soluble polymerizable monomer, polymerizing said monomer, phase-inverting the water-in-oil emulsion to an oil-in-water emulsion, removing the oil phase from the phase-inverted emulsion to form an aqueous latex, adding to the latex an ethylenically unsaturated polymerizable second monomer, and polymerizing said second monomer to produce hydrophobic resin-encapsulated water-insoluble particles; and the resulting encapsulated particles.

Abstract: This invention relates to a method for producing a plasminogen preparation which has been pasteurized to produce a hepatitis safe injectable plasminogen. The method comprises: adding to an aqueous solution of plasminogen the protective agent of methyl lysine ester, or ethyl lysine ester or a hydrochloride salt thereof which has antifibrinolytic acitivity to thereby attach the agent to plasminogen and form a modified plasminogen; and subjecting the resulting modified agent to a heat treatment of at least 60.degree. C. for at least 10 hours. Further, the protective agent may be separated from the modified plasminogen by affinity chromatography.